A follow-up study of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients

Trial Profile

A follow-up study of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 New trial record
    • 16 Aug 2017 According to an ASIT biotech media release, A subset of the 36 initially randomized patients (27 treated with hdm-ASIT+™ and 9 with placebo) will undergo a complementary medical visit in order to assess their reactivity score to a CPT and their titles of house dust mite allergen specific antibodies (IgG, IgG4, IgE and blocking antibodies).
    • 16 Aug 2017 According to an ASIT biotech media release, the company has received the approval from the regulatory authorities and ethical committee to start a follow-up study with the patients enrolled during the Phase II (NCT03094845) clinical trial of its product candidate for house dust mite rhinitis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top